Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$80.37 USD

80.37
10,826,887

+0.93 (1.17%)

Updated Aug 7, 2025 04:02 PM ET

After-Market: $80.36 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.

    Nalak Das headshot

    Dow Posts Robust Daily Gains: 3 Top-Ranked Picks

    by Nalak Das

    U.S. stock markets have remained mostly volatile in 2018 so far. Strong first-quarter earnings results failed to uplift investor sentiment due to several reasons which includes trade conflict and inflationary expectations.

      Zacks Equity Research

      Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More

      by Zacks Equity Research

      The pharma/biotech industry has witnessed a mixed first-quarter earnings picture so far. Let's see what's in store for some of the smaller players.

        Zacks Equity Research

        Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat

        by Zacks Equity Research

        Aduro's (ADRO) loss in Q1 narrows from the estimate. Moreover, revenues top the same and surge substantially year over year on receipt of a milestone payment.

          Swarup Gupta headshot

          Dow 30 Stock Roundup: AAPL, DWDP, CVX, MRK, MCD, PFE Beat on Earnings

          by Swarup Gupta

          The Dow endured a particularly tough week, ending with marginal gains for the first time only on Thursday.

            Zacks Equity Research

            Exelixis (EXEL) Q1 Earnings & Sales Top on Cabometyx Strength

            by Zacks Equity Research

            Exelixis (EXEL) posted a strong performance in the first-quarter as lead drug Cabometyx made further inroads in the RCC market.

              Zacks Equity Research

              Company News for May 2, 2018

              by Zacks Equity Research

              Companies In The News are: PFE,MRK,THC,BP

                Zacks Equity Research

                Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV

                by Zacks Equity Research

                Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.

                  Zacks Equity Research

                  Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates

                  by Zacks Equity Research

                  Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.

                    Zacks Equity Research

                    Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook

                    by Zacks Equity Research

                    Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.

                      Zacks Equity Research

                      ADP Job Data, Q1 Earnings In Focus

                      by Zacks Equity Research

                      ADP Job Data, Q1 Earnings In Focus

                        Mark Vickery headshot

                        Jobs Week Shows New Wage Growth (and Lack Thereof)

                        by Mark Vickery

                        Paychex reported small-business jobs and wage growth for last month, and the results are definitely interesting.

                          Zacks Equity Research

                          Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat

                          by Zacks Equity Research

                          Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.

                            Zacks Equity Research

                            Merck (MRK) Tops on Q1 Earnings, Misses Sales

                            by Zacks Equity Research

                            Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. The company raises outlook for 2018.

                              Zacks Equity Research

                              Will Agenus (AGEN) Disappoint Investors This Earnings Season?

                              by Zacks Equity Research

                              Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.

                                Zacks Equity Research

                                Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More

                                by Zacks Equity Research

                                Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.

                                  Zacks Equity Research

                                  HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?

                                  by Zacks Equity Research

                                  Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.

                                    Zacks Equity Research

                                    Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top

                                    by Zacks Equity Research

                                    Seattle Genetics (SGEN) first-quarter earnings miss estimates while sales beat the same.

                                      Zacks Equity Research

                                      Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark

                                      by Zacks Equity Research

                                      Sanofi (SNY) beat earnings but missed sales estimates in the first quarter of 2018 owing to exchange rate effects and struggling diabetes and cardiovascular unit.

                                        Zacks Equity Research

                                        Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?

                                        by Zacks Equity Research

                                        Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.

                                          Zacks Equity Research

                                          Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

                                          by Zacks Equity Research

                                          Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.

                                            Zacks Equity Research

                                            Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?

                                            by Zacks Equity Research

                                            With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.

                                              Zacks Equity Research

                                              Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?

                                              by Zacks Equity Research

                                              While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

                                                Zacks Equity Research

                                                Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up

                                                by Zacks Equity Research

                                                Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.

                                                  Sweta Killa headshot

                                                  Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

                                                  by Sweta Killa

                                                  Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.